PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company
Enters agreement with intention to divest Applied, Food and Enterprise Services businesses
1
08, 2022
16
05, 2022
PerkinElmer Expands Genomic Testing Services with Ultrarapid Whole Genome Sequencing
WALTHAM, Mass. – May 16, 2022 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the availability of ultrarapid whole genome sequencing (urWGS) through PerkinElmer Genomics. This addition to the Company’s portfolio of whole genome sequencing (WGS) offerings provides physicians with comprehensive, meaningful results in five days to help inform clinical management and improve outcomes for critically ill patients in neonatal and pediatric intensive care units (NICUs and PICUs). With many genetic diseases being chronic and progressive in nature, reducing the time to reaching an accurate diagnosis can eliminate unnecessary procedures, initiate treatment and improve clinical outcomes.
15
04, 2022
Genomics Testing Companies and Laboratories Combine Efforts to Establish the CardioGenomic Testing Alliance
WASHINGTON, D.C., March 22, 2022 /PRNewswire/ — Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology.
2
04, 2021
PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive Health Management
WALTHAM, Massachusetts – (BUSINESS WIRE) – Today, in collaboration with Helix, PerkinElmer, Inc., a global leader committed to innovating for a healthier world, launched GenePrism: Actionable Insights, a new genetic screening test, offering the most comprehensive clinical-grade DNA sequencing and interpretation on the market right now, for anyone who wants to learn about underlying disease risks.
24
07, 2019
PerkinElmer and EverlyWell Announce Collaboration to Expand U.S. At-Home Health Test Market
WALTHAM, Massachusetts, and AUSTIN, Texas – July 24, 2019 – Today, PerkinElmer, Inc. and EverlyWell, Inc. announced a new collaboration designed to accelerate innovation in and accessibility of consumer-initiated health testing, by adding PerkinElmer’s CLIA-certified and CAP-accredited lab facilities to EverlyWell’s network of laboratory providers.
15
10, 2018
The Lantern Project from Sanofi Genzyme and PerkinElmer Expands Access to Free Diagnostic Genetic Testing for a Number of Lysosomal Storage Disorders
CAMBRIDGE, Massachusetts, Oct. 15, 2018 /PRNewswire/ — Patients with rare genetic diseases can face a difficult path to a proper diagnosis.
13
04, 2018
PerkinElmer Sponsors the ACMG Foundation’s Day of Caring Event
Each year, the ACMG Foundation for Genetic and Genomic Medicine with the support of our dedicated corporate partners and medical genetics and genomics professionals from across the country, host the ACMGF Day of Caring event during ACMG’s Annual Meeting.
10
04, 2018
PerkinElmer Collaborates with Helix to Drive Innovation in Exome-Based Personal Genomics
WALTHAM, Mass.–(BUSINESS WIRE) – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced a collaboration with Helix, a personal genomics company, to develop and commercialize exome sequencing-based tests that will empower consumers to make proactive health management decisions.
5
04, 2018
Parent Project Muscular Dystrophy Selects PerkinElmer to Support Decode Duchenne Program
WALTHAM, Mass.–(BUSINESS WIRE)– PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that Parent Project Muscular Dystrophy (PPMD) has selected the Company to provide genetic testing for its Decode Duchenne program.
16
03, 2018
PerkinElmer Genomics Opens New State-Of-The-Art Laboratory
PerkinElmer Genomics is very proud to announce the opening of our new state-of-the-art laboratory in Pittsburgh, PA.